A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors-Reference-Cited by-同舟云学术

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors

Published:1998-11 Issue:6 Volume:4 Page:790-798
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

Lusher ,Roberts ,Davignon ,Joist ,Smith ,Shapiro ,Laurian ,Kasper ,Mannucci ,

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2516.1998.00209.x/fullpdf

Reference34 articles.

1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs;Ehrenforth;Lancet,1992

2. Hoyer LW The incidence of factor VIII inhibitors in patients with severe haemophilia A Inhibitors to Coagulation Factors,

3. Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A;Lusher;N␣Engl J Med,1993

4. Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with haemophilia A;Bray;Blood,1994

5. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII;Addiego;Lancet,1993

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Site-directed mutagenesis of tissue factor pathway inhibitor–binding exosite D60A on factor VII results in a new factor VII variant with lower coagulant activity;Research and Practice in Thrombosis and Haemostasis;2024-01

2. The Pharmacokinetics and Pharmacodynamics of A Novel Recombinant Activated Human Factor VII, GEN-0828, in Hemophilia B Mice;Journal of Pharmaceutical Sciences;2023-03

3. Inhibitors in Hemophilia A;Advances in Hemophilia Treatment;2022

4. In vitro characterization of CT‐001—a short‐acting factor VIIa with enhanced prohemostatic activity;Research and Practice in Thrombosis and Haemostasis;2021-06-30

5. Use of recombinant activated factor VII for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia: A systematic review and meta-analysis of randomized controlled trials;Journal of Critical Care;2021-04